BioAge Labs, Inc. (BIOA): Cash & Equivalents
$188.89M
As of 2025-12-31
$73.96M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $188.89M | -46.7% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $354.35M | n/m | 2026-03-24, Balance as of period end |
| 2023-12-31 | $21.64M | n/a | 2025-03-20, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $188.89M | -46.7% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $52.33M | -87.8% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
Compare BIOA, PGEN, PRTA, ROIV side by side · Screen every company in Pharmaceutical Preparations ↗